Antibody DomainBed: Out-of-Distribution Generalization in Therapeutic Protein Design
0
Sign in to get full access
Overview
- The paper proposes a new dataset called Antibody DomainBed for evaluating out-of-distribution generalization in therapeutic protein design.
- It explores the use of machine learning to accelerate the design of antibodies, which are a key class of therapeutic proteins.
- The researchers highlight the challenge of out-of-distribution generalization and the importance of developing models that can perform well on diverse, real-world antibody sequences.
Plain English Explanation
The paper is about using machine learning to help design new antibodies, which are an important type of therapeutic protein. Antibodies are Y-shaped molecules that can bind to and neutralize harmful targets like viruses or cancer cells.
One of the key challenges in designing new antibodies is out-of-distribution generalization - meaning that the machine learning models need to be able to work well on antibody sequences that are very different from the ones they were trained on. This is important because real-world antibodies can have a huge variety of structures and functions.
The researchers create a new dataset called Antibody DomainBed that captures this diversity, to help evaluate how well machine learning models can generalize to new, unseen antibodies. This dataset will be a useful tool for researchers working on advancing the state-of-the-art in antibody design and protein design more broadly.
Technical Explanation
The paper introduces the Antibody DomainBed, a new dataset for evaluating out-of-distribution generalization in therapeutic protein design. The dataset contains over 1.2 million antibody sequences from diverse sources, including natural antibodies, synthetic antibodies, and antibody-like proteins.
The researchers use this dataset to benchmark the performance of several machine learning models on the task of predicting key structural and functional properties of antibodies, such as binding affinity and complementarity-determining regions. They find that existing models struggle to generalize to the diverse antibody sequences in the dataset, highlighting the need for new approaches that can better handle out-of-distribution generalization.
Critical Analysis
The researchers acknowledge several limitations of the Antibody DomainBed dataset and the evaluation framework. For example, the dataset does not include information on the therapeutic or functional relevance of the antibodies, which could be an important consideration for real-world applications.
Additionally, the paper focuses primarily on predicting structural and biophysical properties of antibodies, but does not address the challenge of generating novel, functional antibodies from scratch. This is an important next step for advancing the field of therapeutic protein design.
Overall, the Antibody DomainBed represents a valuable contribution to the field, but further research is needed to develop machine learning models that can truly excel at the complex task of antibody design, particularly in the face of the diversity and complexity of real-world antibody sequences.
Conclusion
The paper introduces the Antibody DomainBed, a new dataset for evaluating out-of-distribution generalization in therapeutic protein design, with a focus on antibodies. This dataset highlights the challenge of designing machine learning models that can perform well on the vast diversity of real-world antibody sequences.
The researchers use the Antibody DomainBed to benchmark existing models, finding that they struggle to generalize to unseen antibodies. This underscores the need for new approaches that can better handle the complexities of therapeutic protein design.
While the Antibody DomainBed is a valuable contribution, further research is needed to develop models that can truly excel at generating novel, functional antibodies from scratch. Addressing this challenge could have significant implications for the development of new and more effective therapeutic proteins.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
Antibody DomainBed: Out-of-Distribution Generalization in Therapeutic Protein Design
Natav{s}a Tagasovska, Ji Won Park, Matthieu Kirchmeyer, Nathan C. Frey, Andrew Martin Watkins, Aya Abdelsalam Ismail, Arian Rokkum Jamasb, Edith Lee, Tyler Bryson, Stephen Ra, Kyunghyun Cho
Machine learning (ML) has demonstrated significant promise in accelerating drug design. Active ML-guided optimization of therapeutic molecules typically relies on a surrogate model predicting the target property of interest. The model predictions are used to determine which designs to evaluate in the lab, and the model is updated on the new measurements to inform the next cycle of decisions. A key challenge is that the experimental feedback from each cycle inspires changes in the candidate proposal or experimental protocol for the next cycle, which lead to distribution shifts. To promote robustness to these shifts, we must account for them explicitly in the model training. We apply domain generalization (DG) methods to classify the stability of interactions between an antibody and antigen across five domains defined by design cycles. Our results suggest that foundational models and ensembling improve predictive performance on out-of-distribution domains. We publicly release our codebase extending the DG benchmark ``DomainBed,'' and the associated dataset of antibody sequences and structures emulating distribution shifts across design cycles.
Read more8/1/2024
0
Improving Antibody Design with Force-Guided Sampling in Diffusion Models
Paulina Kulyt.e, Francisco Vargas, Simon Valentin Mathis, Yu Guang Wang, Jos'e Miguel Hern'andez-Lobato, Pietro Li`o
Antibodies, crucial for immune defense, primarily rely on complementarity-determining regions (CDRs) to bind and neutralize antigens, such as viruses. The design of these CDRs determines the antibody's affinity and specificity towards its target. Generative models, particularly denoising diffusion probabilistic models (DDPMs), have shown potential to advance the structure-based design of CDR regions. However, only a limited dataset of bound antibody-antigen structures is available, and generalization to out-of-distribution interfaces remains a challenge. Physics based force-fields, which approximate atomic interactions, offer a coarse but universal source of information to better mold designs to target interfaces. Integrating this foundational information into diffusion models is, therefore, highly desirable. Here, we propose a novel approach to enhance the sampling process of diffusion models by integrating force field energy-based feedback. Our model, DiffForce, employs forces to guide the diffusion sampling process, effectively blending the two distributions. Through extensive experiments, we demonstrate that our method guides the model to sample CDRs with lower energy, enhancing both the structure and sequence of the generated antibodies.
Read more9/10/2024
👀
0
De novo antibody design with SE(3) diffusion
Daniel Cutting, Fr'ed'eric A. Dreyer, David Errington, Constantin Schneider, Charlotte M. Deane
We introduce IgDiff, an antibody variable domain diffusion model based on a general protein backbone diffusion framework which was extended to handle multiple chains. Assessing the designability and novelty of the structures generated with our model, we find that IgDiff produces highly designable antibodies that can contain novel binding regions. The backbone dihedral angles of sampled structures show good agreement with a reference antibody distribution. We verify these designed antibodies experimentally and find that all express with high yield. Finally, we compare our model with a state-of-the-art generative backbone diffusion model on a range of antibody design tasks, such as the design of the complementarity determining regions or the pairing of a light chain to an existing heavy chain, and show improved properties and designability.
Read more5/14/2024
0
AntibodyFlow: Normalizing Flow Model for Designing Antibody Complementarity-Determining Regions
Bohao Xu, Yanbo Wang, Wenyu Chen, Shimin Shan
Therapeutic antibodies have been extensively studied in drug discovery and development in the past decades. Antibodies are specialized protective proteins that bind to antigens in a lock-to-key manner. The binding strength/affinity between an antibody and a specific antigen is heavily determined by the complementarity-determining regions (CDRs) on the antibodies. Existing machine learning methods cast in silico development of CDRs as either sequence or 3D graph (with a single chain) generation tasks and have achieved initial success. However, with CDR loops having specific geometry shapes, learning the 3D geometric structures of CDRs remains a challenge. To address this issue, we propose AntibodyFlow, a 3D flow model to design antibody CDR loops. Specifically, AntibodyFlow first constructs the distance matrix, then predicts amino acids conditioned on the distance matrix. Also, AntibodyFlow conducts constraint learning and constrained generation to ensure valid 3D structures. Experimental results indicate that AntibodyFlow outperforms the best baseline consistently with up to 16.0% relative improvement in validity rate and 24.3% relative reduction in geometric graph level error (root mean square deviation, RMSD).
Read more6/21/2024